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Abstract
Very little guidance exists to help 
clinicians and families decide whether 
mammograms are useful in elderly 
women with Alzheimer’s Disease (AD). 
We present a case of a patient with 
moderate AD who had a positive 
mammogram and discuss the dilemma 
faced by the family and clinician in 
deciding what was best to do for the 
patient. In this case, the family opted for 
breast conserving surgery (BCS) followed 
by palliative care which brought up the 
question of whether screening was 
appropriate with this treatment goal in 
mind. We reviewed the literature on AD 
and breast cancer screening and 
summarize these findings in our 
discussion.
Introduction
Alzheimer’s Disease (AD) is 
the sixth leading cause of death in 
the United States with a current 
prevalence of about 5.4 million 
Americans and expected to rise 
to 16 million by the year 2050. In 
2011, nearly $183 billion was spent 
on health care, long term care, 
and hospice care costs for people 
with AD and other dementias.1 
Few articles exist that help guide 
clinicians on whether screening 
mammograms would benefit patients 
with AD. We present the case of 
a patient with moderate AD who 
continued to receive mammograms 
and the lesson learned from this 
case when it became evident that 
the family did not want aggressive 
treatment of the patient’s cancer.
Case presentation
An 82-year-old female presented 
with memory loss at age 75 and 
her mini-mental status at that time 
was 29/30 (normal 26-30). She had 
a gradual loss of memory over the 
ensuing 7 years and was diagnosed 
with AD. At age 82 she was 
ambulating without assistance and, 
aside from a history of osteoporosis, 
she had no other medical problems. 
She continued to have regular 
preventive care including yearly 
mammograms, but a dilemma arose 
when her mammogram showed a 14 
mm lesion in the left breast highly 
suspicious for cancer. Unfortunately, 
her memory had declined to a mini-
mental status score of 19 consistent 
with moderate dementia and she 
was unable to make decisions for 
herself. After discussion with the 
family, the patient was referred 
to a surgeon and a lumpectomy 
was performed which revealed a 
1.3 cm grade 1 infiltrating lobular 
carcinoma that was completely 
excised. The tumor was ER positive, 
PR negative and Her2 negative. 
At this point the family decided 
not to put the patient through any 
more treatment. She lived two 
more years and over that time had 
a gradual decline in her functional 
status and memory, eventually 
becoming bedfast and requiring 
nursing home care before she died.
Discussion
This 82-year-old patient with 
moderate AD continued to receive 
breast cancer screening which 
may not have been appropriate. 
Some may argue that even healthy 
82–year-old women should not 
receive breast cancer screening. The 
US Preventive Services Task Force 
(USPSTF) concluded that evidence as 
to whether breast cancer screening 
for women 75 years or older has any 
benefit is lacking since randomized 
controlled trials of breast cancer 
screening did not include this age 
group.2 The American Geriatric 
Society Clinical Practice Committee 
recommends biennial or every three 
year screening for women over 
age 75 years as long as their life 
expectancy is at least four years.3 
The Cochrane review analysis of 
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seven randomized trials comparing 
screening mammography versus 
no screening revealed three well 
designed trials which did not show 
any significant decrease in breast 
cancer mortality and four less 
optimally designed trials showing a 
significant decrease in breast cancer 
mortality.4 The overall evidence for a 
benefit of screening mammography 
in women over age 75 is not clear.
The ethical dilemma of whether 
or not to recommend screening 
mammography among AD patients 
has been discussed by Raik et 
al.5 They considered the benefits 
such as improved survival from 
early detection and treatment, and 
reassurance of negative examination, 
which will possibly benefit 
mildly impaired patients, but not 
moderately or severely demented 
patients who may not understand 
the reassurance of a negative scan. 
The burdens of mammography 
can be due to overdiagnosis with 
false positive screening results 
leading to diagnostic mammograms 
and biopsies or overtreatment 
of premalignant conditions such 
as ductal carcinoma in situ. 
Additional harm may occur from 
subjecting cognitively impaired 
patients to a procedure that they 
do not understand. Raik et al 
suggested withholding screening 
mammography for patients with 
advanced dementia, significant 
comorbidity, or a life expectancy of 
less than 5 years. However, patients 
with mild dementia who may have 
the capability to understand benefits 
and harms should be given the 
opportunity to decide for themselves 
about screening after a discussion 
with their primary care provider. 
When considering breast cancer 
screening in patients with AD, the 
goals of care for the individual 
patient should be discussed. Goals 
of care have been classified by 
Sachs into prolongation of life, 
some limitations on life prolonging 
treatment weighing treatment 
benefits and burdens, and palliation.6 
Although for most people, including 
many AD patients, life prolongation 
is the major goal, this may change 
as the disease progresses. Cassel 
suggested that a good rule to follow 
would be that if surgery would 
be performed should a lump be 
discovered then mammography 
should be continued.7 A study about 
the importance of screening for 
breast cancer involving 23 caregivers 
of women with dementia revealed 
that most caregivers of women with 
mild to moderate dementia have the 
intent to continue screening, while 
caregivers of women with severe 
dementia did not perceive screening 
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as important.8 Moreover, similar to 
the family in our case, their opinions 
on appropriate treatment if the 
patient with AD developed breast 
cancer was toward non-aggressive or 
comfort care. Unfortunately, families 
often schedule the mammogram 
without discussing it first with the 
primary care provider. In order 
to avoid being surprised with 
the dilemma of dealing with an 
abnormal mammogram in a patient 
with AD whose goal is palliation, 
preemptive discussion about the 
appropriateness of continuing 
screening mammography needs 
to take place at least annually. 
Older women with a life 
expectancy of less than five years are 
less likely to benefit from screening 
mammography. A study of the 
impact of cognitive impairment on 
screening mammography found 
that although women with severe 
cognitive impairment have a lower 
rate of mammogram utilization 
compared to women without 
cognitive impairment, an estimated 
120,000 screening mammograms 
were performed among women 
with severe cognitive impairment, 
a group with a median survival of 
just 3.3 years.9 This represents a 
use of medical resources that may 
not be having much benefit. Larson 
et al10 showed that unsteady gait, 
wandering, incontinence of urine, 
low score on mini-mental status exam 
at presentation or drop of 5 points 
in first year, and pre-existing heart 
disease or diabetes predict shorter 
life expectancy among patients with 
AD. Physicians need to be aware of 
factors causing shortened survival 
in AD so they can better advise 
their patients and families on the 
merits of breast cancer screening. 
Our patient’s family opted for 
breast conserving surgery (BCS) 
alone as treatment for her early stage 
breast cancer. This is a fairly common 
choice according to a cohort study of 
50,460 breast cancer patients of whom 
1,935 patients had a diagnosis of AD 
which concluded that women with 
AD more often chose BCS than those 
without AD.11 Moreover, the AD 
patients were less likely to receive 
any treatment for their breast cancer. 
Different treatment modalities 
among patients over age 70 years 
with early stage breast cancer have 
been discussed by the International 
Society of Geriatric Oncology.12 BCS is 
currently preferred over mastectomy 
especially in the elderly as it may 
lead to a better quality of life with 
no difference in overall survival or 
disease-free survival compared to 
total mastectomy, however local 
recurrence is increased with BCS 
alone. Radiotherapy reduces local 
recurrence rate, however, there is 
controversy in its overall survival 
benefits. Patient’s health status, 
functional capacity, comorbidities, 
and risk of local recurrence should 
be considered before offering 
radiotherapy. Adjuvant hormonal 
therapy with either tamoxifen or 
aromatase inhibitors typically will 
benefit older patients with hormone 
sensitive breast cancers. The decision 
to give adjuvant chemotherapy 
should include consideration 
of absolute benefits, individual 
patient tolerance, life expectancy, 
and other comorbidities.11 
In conclusion, screening 
mammograms should not be used 
in severely demented patients. 
Those with mild or moderate AD 
should decide about screening based 
on comorbidities, life expectancy, 
and intent to treat the cancer once 
discovered. Healthcare providers 
of patients with AD should have 
periodic discussions regarding 
the appropriateness of screening 
mammograms as the disease 
progresses and goals of care change.
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37.  Regarding the evidence for screening 
mammograms for women over age 75 years:
 a.		The	USPSTF	states	that	screening	is	definitely	
indicated and supported by evidence.
 b.  The American Geriatrics Society states that 
mammograms could be offered every 2-3 years in 
the elderly with at least 4 years of life expectancy.
 c.  Most clinical trials of screening mammography 
included women over age 75.
 d.  The best designed clinical trials showed 
a decrease in breast cancer mortality.
38.  According to Raik et al, which of the 
following was appropriate:
 a.  Mammograms should be withheld from patients 
with less than 10 years life expectancy
 b.  Patients with mild to moderate dementia would 
not	benefit	from	screening	mammograms
 c.  Patients with severe dementia would not 
benefit	from	reassurance	of	a	negative	exam.
 d.  One of the burdens of mammography 
is the cost to the patient.
39.  Regarding treatment of breast cancer 
in Alzheimer’s disease
 a.  Total mastectomy is preferred by most patients.
 b.  Radiation therapy helps prevent 
distant metastasis.
 c.  Hormonal therapies are rarely used in the elderly.
 d.  Breast conserving therapy for early stage 
disease has no difference in survival 
compared to total mastectomy.
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